CLN-0046: Treatment of AMD Subjects With OTX-TKI

Inclusion Criteria: * Are at least 50 years of age * Are eligible for standard therapy * Have active primary CNVM secondary to AMD, either newly diagnosed or previously treated with documented response to anti-VEGF therapy in the study eye \[primary subfoveal CNV secondary to AMD including juxtafoveal lesions that affect the fovea\] documented by FA and SD-OCT * Are female who is postmenopausal for at least 12 months prior to screening or surgically sterile; or male or female of childbearing potential willing to use two forms of adequate contraception * Are able and willing to comply with all study requirements and visits Exclusion Criteria: * Have previous laser photocoagulation to the center of the fovea in the study eye * Have participated in any study involving an investigational drug either in the U.S. or outside the U.S. within the past 30 days * Are an employee of the site that is directly involved in the management, administration, or support of the study, or be an immediate family member of the same * Have a presence of a disease other than CNVM due to AMD in the study eye that could affect vision or safety assessments